Complete axillary lymph node dissection for stage I-II carcinoma of the breast

D. N. Danforth, P. A. Findlay, H. D. McDonald, M. E. Lippman, C. M. Reichert, T. d'Angelo, C. R. Gorrell, N. L. Gerber, A. S. Lichter, S. A. Rosenberg

Research output: Contribution to journalArticle

Abstract

We reviewed the complete axillary dissection specimens of 136 patients with stage I-II breast cancer to clarify the distribution of axillary lymph node metastases in this disease. Our series included 71 patients undergoing axillary dissection as part of a modified radical mastectomy (MRM) and 65 patients undergoing axillary dissection in conjunction with conservative surgery of the breast and definitive postoperative breast radiotherapy (CAD). These two groups of patients were comparable according to age, menopausal status, tumor size, and clinical stage. In all patients the pectoralis minor muscle was excised and all axillary tissue removed. Each specimen contained a median of 23 lymph nodes. The axillary levels (I, II, III) were determined according to the relationship of axillary tissue to the pectoris minor muscle (lateral, inferior, medial). Thirty-nine percent of the lymph nodes were contained in level I, 41% in level II, and 20% in level III. There were no significant differences noted in the number of lymph nodes or in the distribution of lymph nodes according to axillary level between dissections performed as part of the MRM or those done as a single procedure (CAD). Sixty-five patients (47.8%) had one or more positive lymph nodes in their axillary specimens. The clinical and pathologic stage was determined and compared for all patients. Among patients judged to have a clinically negative axilla, 37.6% had histologically positive lymph nodes (clinical false-negative rate). For patients with a clinically positive axilla, 11.1% had, histologically, no evidence of metastatic disease (clinical false-positive rate). When the distribution of lymph node metastases according to axillary level was studied, it was found that 29.2% of lymph node-positive patients (or 14.0% of all patients) had metastases only to level II and/or III of the axilla, with level I being negative (skip metastases). This incidence of skip metastases was greater among clinically node-negative than among clinically node-positive patients, but was not related to the size or location of the primary tumor in the breast. In addition, it was found that 20.0% of lymph node-positive patients (or 9.6% of all patients) were converted from three or fewer to four or more positive nodes by analysis of lymph nodes contained in levels II and III. This conversion from three or fewer to four or more positive nodes was due primarily to information contained in level II, with level III contributing to a smaller degree. We concluded from our findings and a review of the literature that metastases to only the higher axillary levels occur in a significant number of patients with stage I-II breast cancer. Analysis of axillary lymph nodes provides important information for staging and prognostic purposes and for determining the need for adjuvant chemotherapy. A dissection of at least levels I and II of the axilla is the minimum procedure that should be performed in patients with stage I-II breast cancer. The inclusion of level III may provide additional information in a small number of patients; however, level III should be included in the dissection in clinically node-positive patients to obtain local control of disease.

Original languageEnglish (US)
Pages (from-to)655-662
Number of pages8
JournalJournal of Clinical Oncology
Volume4
Issue number5
StatePublished - 1986
Externally publishedYes

Fingerprint

Lymph Node Excision
Breast Neoplasms
Lymph Nodes
Dissection
Axilla
Neoplasm Metastasis
Modified Radical Mastectomy
Breast
Pectoralis Muscles
Adjuvant Chemotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Danforth, D. N., Findlay, P. A., McDonald, H. D., Lippman, M. E., Reichert, C. M., d'Angelo, T., ... Rosenberg, S. A. (1986). Complete axillary lymph node dissection for stage I-II carcinoma of the breast. Journal of Clinical Oncology, 4(5), 655-662.

Complete axillary lymph node dissection for stage I-II carcinoma of the breast. / Danforth, D. N.; Findlay, P. A.; McDonald, H. D.; Lippman, M. E.; Reichert, C. M.; d'Angelo, T.; Gorrell, C. R.; Gerber, N. L.; Lichter, A. S.; Rosenberg, S. A.

In: Journal of Clinical Oncology, Vol. 4, No. 5, 1986, p. 655-662.

Research output: Contribution to journalArticle

Danforth, DN, Findlay, PA, McDonald, HD, Lippman, ME, Reichert, CM, d'Angelo, T, Gorrell, CR, Gerber, NL, Lichter, AS & Rosenberg, SA 1986, 'Complete axillary lymph node dissection for stage I-II carcinoma of the breast', Journal of Clinical Oncology, vol. 4, no. 5, pp. 655-662.
Danforth DN, Findlay PA, McDonald HD, Lippman ME, Reichert CM, d'Angelo T et al. Complete axillary lymph node dissection for stage I-II carcinoma of the breast. Journal of Clinical Oncology. 1986;4(5):655-662.
Danforth, D. N. ; Findlay, P. A. ; McDonald, H. D. ; Lippman, M. E. ; Reichert, C. M. ; d'Angelo, T. ; Gorrell, C. R. ; Gerber, N. L. ; Lichter, A. S. ; Rosenberg, S. A. / Complete axillary lymph node dissection for stage I-II carcinoma of the breast. In: Journal of Clinical Oncology. 1986 ; Vol. 4, No. 5. pp. 655-662.
@article{2dbd478b644345cbb2962f29a8be3248,
title = "Complete axillary lymph node dissection for stage I-II carcinoma of the breast",
abstract = "We reviewed the complete axillary dissection specimens of 136 patients with stage I-II breast cancer to clarify the distribution of axillary lymph node metastases in this disease. Our series included 71 patients undergoing axillary dissection as part of a modified radical mastectomy (MRM) and 65 patients undergoing axillary dissection in conjunction with conservative surgery of the breast and definitive postoperative breast radiotherapy (CAD). These two groups of patients were comparable according to age, menopausal status, tumor size, and clinical stage. In all patients the pectoralis minor muscle was excised and all axillary tissue removed. Each specimen contained a median of 23 lymph nodes. The axillary levels (I, II, III) were determined according to the relationship of axillary tissue to the pectoris minor muscle (lateral, inferior, medial). Thirty-nine percent of the lymph nodes were contained in level I, 41{\%} in level II, and 20{\%} in level III. There were no significant differences noted in the number of lymph nodes or in the distribution of lymph nodes according to axillary level between dissections performed as part of the MRM or those done as a single procedure (CAD). Sixty-five patients (47.8{\%}) had one or more positive lymph nodes in their axillary specimens. The clinical and pathologic stage was determined and compared for all patients. Among patients judged to have a clinically negative axilla, 37.6{\%} had histologically positive lymph nodes (clinical false-negative rate). For patients with a clinically positive axilla, 11.1{\%} had, histologically, no evidence of metastatic disease (clinical false-positive rate). When the distribution of lymph node metastases according to axillary level was studied, it was found that 29.2{\%} of lymph node-positive patients (or 14.0{\%} of all patients) had metastases only to level II and/or III of the axilla, with level I being negative (skip metastases). This incidence of skip metastases was greater among clinically node-negative than among clinically node-positive patients, but was not related to the size or location of the primary tumor in the breast. In addition, it was found that 20.0{\%} of lymph node-positive patients (or 9.6{\%} of all patients) were converted from three or fewer to four or more positive nodes by analysis of lymph nodes contained in levels II and III. This conversion from three or fewer to four or more positive nodes was due primarily to information contained in level II, with level III contributing to a smaller degree. We concluded from our findings and a review of the literature that metastases to only the higher axillary levels occur in a significant number of patients with stage I-II breast cancer. Analysis of axillary lymph nodes provides important information for staging and prognostic purposes and for determining the need for adjuvant chemotherapy. A dissection of at least levels I and II of the axilla is the minimum procedure that should be performed in patients with stage I-II breast cancer. The inclusion of level III may provide additional information in a small number of patients; however, level III should be included in the dissection in clinically node-positive patients to obtain local control of disease.",
author = "Danforth, {D. N.} and Findlay, {P. A.} and McDonald, {H. D.} and Lippman, {M. E.} and Reichert, {C. M.} and T. d'Angelo and Gorrell, {C. R.} and Gerber, {N. L.} and Lichter, {A. S.} and Rosenberg, {S. A.}",
year = "1986",
language = "English (US)",
volume = "4",
pages = "655--662",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "5",

}

TY - JOUR

T1 - Complete axillary lymph node dissection for stage I-II carcinoma of the breast

AU - Danforth, D. N.

AU - Findlay, P. A.

AU - McDonald, H. D.

AU - Lippman, M. E.

AU - Reichert, C. M.

AU - d'Angelo, T.

AU - Gorrell, C. R.

AU - Gerber, N. L.

AU - Lichter, A. S.

AU - Rosenberg, S. A.

PY - 1986

Y1 - 1986

N2 - We reviewed the complete axillary dissection specimens of 136 patients with stage I-II breast cancer to clarify the distribution of axillary lymph node metastases in this disease. Our series included 71 patients undergoing axillary dissection as part of a modified radical mastectomy (MRM) and 65 patients undergoing axillary dissection in conjunction with conservative surgery of the breast and definitive postoperative breast radiotherapy (CAD). These two groups of patients were comparable according to age, menopausal status, tumor size, and clinical stage. In all patients the pectoralis minor muscle was excised and all axillary tissue removed. Each specimen contained a median of 23 lymph nodes. The axillary levels (I, II, III) were determined according to the relationship of axillary tissue to the pectoris minor muscle (lateral, inferior, medial). Thirty-nine percent of the lymph nodes were contained in level I, 41% in level II, and 20% in level III. There were no significant differences noted in the number of lymph nodes or in the distribution of lymph nodes according to axillary level between dissections performed as part of the MRM or those done as a single procedure (CAD). Sixty-five patients (47.8%) had one or more positive lymph nodes in their axillary specimens. The clinical and pathologic stage was determined and compared for all patients. Among patients judged to have a clinically negative axilla, 37.6% had histologically positive lymph nodes (clinical false-negative rate). For patients with a clinically positive axilla, 11.1% had, histologically, no evidence of metastatic disease (clinical false-positive rate). When the distribution of lymph node metastases according to axillary level was studied, it was found that 29.2% of lymph node-positive patients (or 14.0% of all patients) had metastases only to level II and/or III of the axilla, with level I being negative (skip metastases). This incidence of skip metastases was greater among clinically node-negative than among clinically node-positive patients, but was not related to the size or location of the primary tumor in the breast. In addition, it was found that 20.0% of lymph node-positive patients (or 9.6% of all patients) were converted from three or fewer to four or more positive nodes by analysis of lymph nodes contained in levels II and III. This conversion from three or fewer to four or more positive nodes was due primarily to information contained in level II, with level III contributing to a smaller degree. We concluded from our findings and a review of the literature that metastases to only the higher axillary levels occur in a significant number of patients with stage I-II breast cancer. Analysis of axillary lymph nodes provides important information for staging and prognostic purposes and for determining the need for adjuvant chemotherapy. A dissection of at least levels I and II of the axilla is the minimum procedure that should be performed in patients with stage I-II breast cancer. The inclusion of level III may provide additional information in a small number of patients; however, level III should be included in the dissection in clinically node-positive patients to obtain local control of disease.

AB - We reviewed the complete axillary dissection specimens of 136 patients with stage I-II breast cancer to clarify the distribution of axillary lymph node metastases in this disease. Our series included 71 patients undergoing axillary dissection as part of a modified radical mastectomy (MRM) and 65 patients undergoing axillary dissection in conjunction with conservative surgery of the breast and definitive postoperative breast radiotherapy (CAD). These two groups of patients were comparable according to age, menopausal status, tumor size, and clinical stage. In all patients the pectoralis minor muscle was excised and all axillary tissue removed. Each specimen contained a median of 23 lymph nodes. The axillary levels (I, II, III) were determined according to the relationship of axillary tissue to the pectoris minor muscle (lateral, inferior, medial). Thirty-nine percent of the lymph nodes were contained in level I, 41% in level II, and 20% in level III. There were no significant differences noted in the number of lymph nodes or in the distribution of lymph nodes according to axillary level between dissections performed as part of the MRM or those done as a single procedure (CAD). Sixty-five patients (47.8%) had one or more positive lymph nodes in their axillary specimens. The clinical and pathologic stage was determined and compared for all patients. Among patients judged to have a clinically negative axilla, 37.6% had histologically positive lymph nodes (clinical false-negative rate). For patients with a clinically positive axilla, 11.1% had, histologically, no evidence of metastatic disease (clinical false-positive rate). When the distribution of lymph node metastases according to axillary level was studied, it was found that 29.2% of lymph node-positive patients (or 14.0% of all patients) had metastases only to level II and/or III of the axilla, with level I being negative (skip metastases). This incidence of skip metastases was greater among clinically node-negative than among clinically node-positive patients, but was not related to the size or location of the primary tumor in the breast. In addition, it was found that 20.0% of lymph node-positive patients (or 9.6% of all patients) were converted from three or fewer to four or more positive nodes by analysis of lymph nodes contained in levels II and III. This conversion from three or fewer to four or more positive nodes was due primarily to information contained in level II, with level III contributing to a smaller degree. We concluded from our findings and a review of the literature that metastases to only the higher axillary levels occur in a significant number of patients with stage I-II breast cancer. Analysis of axillary lymph nodes provides important information for staging and prognostic purposes and for determining the need for adjuvant chemotherapy. A dissection of at least levels I and II of the axilla is the minimum procedure that should be performed in patients with stage I-II breast cancer. The inclusion of level III may provide additional information in a small number of patients; however, level III should be included in the dissection in clinically node-positive patients to obtain local control of disease.

UR - http://www.scopus.com/inward/record.url?scp=0022637297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022637297&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 655

EP - 662

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 5

ER -